We are a leading healthcare campus encompassing all fields of health: from healthcare and research to teaching and management.
Professionalism, commitment and research by professionals on the Campus are the key elements in offering patients excellent care.
We are committed to research as a tool to provide solutions to the daily challenges we face in the field of medical healthcare.
Thanks to our healthcare, teaching and research potential, we work to incorporate new knowledge to generate value for patients, professionals and the organization itself.
We generate, transform and transmit knowledge in all areas of the health sciences, helping to train the professionals of the future.
We are defined by our vocation for communication. We invite you to share everything that happens at Vall d'Hebron Barcelona Hospital Campus, and our doors are always open.
Hospital donations
Research donations
Dr. Carlos Jiménez Jiménez, Childhood Cancer and Blood Disorders group.
Epigenetic programming during development is essential for the determination of cell lineages, and its alteration contributes to the initiation of embryonal tumors. In neuroblastoma, neural crest progenitors block their natural differentiation course into sympathoadrenergic cells, leading to an aggressive and metastatic pediatric cancer. The study of the epigenetic regulators responsible for oncogenic epigenomic networks is crucial to develop new epigenetic-based therapies against these tumors.
mSWI/SNF ATP-dependent chromatin remodeling complexes act genome-wide translating epigenetic signals into opened chromatin states. With the aim of understanding the role of mSWI/SNF complexes in the control of the oncogenic epigenomes of neuroblastoma, we carried out a functional characterization of these remodelers in neuroblastoma cells by proteomic, transcriptomic and chromatin accessibility approaches, discovering that only the structural disruption of BAF subtype complexes impairs proliferation by promoting cell cycle blockade. Genome-wide chromatin remodeling analysis coupled with whole transcriptome data revealed that BAF disruption results in the epigenetic repression of an extensive invasiveness-related expression program, involving integrins, cadherins and key mesenchymal regulators, thereby reducing extracellular matrix adhesion and invasion in vitro, together with a drastic inhibition of neuroblastoma metastasis initiation and growth in vivo.
We defined a novel ATPase-independent role for BAF complex in the maintenance of an epigenomic program that allows neuroblastoma invasiveness and metastasis, urging the development of new BAF pharmacological structural disruptors for its therapeutic exploitation in metastatic neuroblastoma.
Host: Dr. Miguel Segura, Childhood Cancer and Blood Disorders group.
The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”. Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health). Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information. Legal basis: Consent of the data subject. Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen. Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time. Source: The data subject. Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.